A Phase 3 Multi-Center Open Label Safety Study of RSD1235 in Subjects With Atrial Fibrillation
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Registrational; Therapeutic Use
- Acronyms ACT IV; ACT-4
- Sponsors Astellas Pharma; Cardiome Pharma
- 22 Dec 2007 Status change from in progress to completed.
- 13 Dec 2006 Status change
- 10 Feb 2006 New trial record.